{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T17:53:21Z","timestamp":1793814801401,"version":"4.6.1"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,10,8]],"date-time":"2022-10-08T00:00:00Z","timestamp":1665187200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,10,8]],"date-time":"2022-10-08T00:00:00Z","timestamp":1665187200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Med Case Reports"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Peyronie\u2019s disease is a chronic inflammatory condition of the corpora cavernosa characterized by the formation of plaque in the tunica albuginea, which results in penile deformity. Conservative medical approaches encompass oral, topical, and physical treatment. Only two cases of patients with Peyronie\u2019s disease with complete plaque regression after treatment have been described in literature.<\/jats:p><\/jats:sec><jats:sec><jats:title>Case presentation<\/jats:title><jats:p><jats:italic>Case 1<\/jats:italic>: A 50-year-old Caucasian man with penile pain and double penile curvature of 5\u00b0 (left ventrolateral), palpable nodule, and normal penile rigidity. The patient underwent multimodal therapy (oral antioxidants\u2009+\u2009topical diclofenac gel). At follow-up after over 4\u00a0years of treatment, the patient no longer complained of any penile deformity or pain. Ultrasound examination did not show any plaque.<jats:italic>Case 2<\/jats:italic>: A 26-year-old Caucasian man with lateral-right penile curvature of 30\u00b0 (previous congenital curvature of 15\u00b0), palpable nodule, and normal penile rigidity. The patient underwent multimodal therapy (oral antioxidants\u2009+\u2009topical diclofenac gel\u2009+\u2009penile injections\/pentoxifylline). After 28\u00a0months of treatment, the patient presented a lateral right curve of 15\u00b0 at follow-up, similar to the original congenital penile curvature. Ultrasound examination no longer showed any plaque.<jats:italic>Case 3<\/jats:italic>: A 36-year-old Caucasian man with penile pain and a complex penile curvature of 15\u00b0 and 20\u00b0 (left dorsolateral), palpable nodule, and normal penile rigidity. The patient underwent multimodal therapy (oral antioxidants\u2009+\u2009topical diclofenac gel\u2009+\u2009penile injections\/pentoxifylline). At follow-up after 28 months of treatment, the patient presented a dorsal curve (10\u00b0) similar to the original congenital curvature. Penile palpation did not detect any nodules, and ultrasound no longer showed any plaque.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>This study demonstrates that our multimodal therapy is able to completely regress plaque, as demonstrated in our previously published article. Peyronie\u2019s disease has the potential to be treated conservatively with good results. However, this method of treatment needs to be combined with accurate ultrasound assessment, performed using a sufficiently advanced machine by an experienced operator.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s13256-022-03614-1","type":"journal-article","created":{"date-parts":[[2022,10,7]],"date-time":"2022-10-07T23:05:44Z","timestamp":1665183944000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Patients with Peyronie\u2019s disease achieve complete plaque regression after multimodal treatment with antioxidants: a case series"],"prefix":"10.1186","volume":"16","author":[{"given":"Gianni","family":"Paulis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"De Giorgio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,10,8]]},"reference":[{"issue":"1","key":"3614_CR1","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/S0022-5347(01)65370-9","volume":"157","author":"W Weidner","year":"1997","unstructured":"Weidner W, Schroeder-Printzen I, Weiske WH, et al. Sexual dysfunction in Peyronie\u2019s disease: an analysis of 222 patients without previous local plaque therapy. J Urol. 1997;157(1):325\u20138.","journal-title":"J Urol"},{"issue":"5","key":"3614_CR2","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1038\/sj.ijir.3900877","volume":"14","author":"JP Pryor","year":"2002","unstructured":"Pryor JP, Ralph DJ. Clinical presentations of Peyronie\u2019s disease. Int J Impot Res. 2002;14(5):414\u20137.","journal-title":"Int J Impot Res"},{"issue":"8","key":"3614_CR3","doi-asserted-by":"publisher","first-page":"1985","DOI":"10.1111\/j.1743-6109.2008.00895.x","volume":"5","author":"CJ Nelson","year":"2008","unstructured":"Nelson CJ, Diblasio C, Kendirci M, et al. The chronology of depression and distress in men with Peyronie\u2019s disease. J Sex Med. 2008;5(8):1985\u201390.","journal-title":"J Sex Med"},{"key":"3614_CR4","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/S0022-5347(01)65361-8","volume":"157","author":"CJJ Devine","year":"1997","unstructured":"Devine CJJ, Somers KD, Jordan GH. Proposal: trauma as a cause of Peyronie\u2019s lesion. J Urol. 1997;157:285\u201390.","journal-title":"J Urol"},{"issue":"1","key":"3614_CR5","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/S0022-5347(01)65367-9","volume":"157","author":"KD Somers","year":"1997","unstructured":"Somers KD, Dawson DM. Fibrin deposition in Peyronie\u2019s disease plaque. J Urol. 1997;157(1):311\u20135.","journal-title":"J Urol"},{"issue":"3","key":"3614_CR6","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/j.aju.2013.06.006","volume":"11","author":"AI El-Sakka","year":"2013","unstructured":"El-Sakka AI, Salabas E, Din\u00e7er M. The pathophysiology of Peyronie\u2019s disease. Arab J Urol. 2013;11(3):272\u20137.","journal-title":"Arab J Urol"},{"issue":"5","key":"3614_CR7","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1038\/sj.ijir.3900880","volume":"14","author":"SC Sikka","year":"2002","unstructured":"Sikka SC, Hellstrom WJG. Role of oxidative stress and antioxidants in Peyronie\u2019s disease. Int J Impot Res. 2002;14(5):353\u201360.","journal-title":"Int J Impot Res"},{"key":"3614_CR8","doi-asserted-by":"publisher","first-page":"4653512","DOI":"10.1155\/2017\/4653512","volume":"2017","author":"G Paulis","year":"2017","unstructured":"Paulis G, Romano G, Paulis L, et al. Recent pathophysiological aspects of Peyronie\u2019s disease: role of free radicals, rationale, and therapeutic implications for antioxidant treatment\u2014literature review. Adv Urol. 2017;2017:4653512.","journal-title":"Adv Urol"},{"issue":"2","key":"3614_CR9","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1007\/s11934-020-01024-8","volume":"22","author":"A Yousif","year":"2021","unstructured":"Yousif A, Natale C, Hellstrom WJG. Conservative therapy for Peyronie\u2019s disease: a contemporary review of the literature. Curr Urol Rep. 2021;22(2):6.","journal-title":"Curr Urol Rep"},{"issue":"2","key":"3614_CR10","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1016\/j.sxmr.2020.01.005","volume":"9","author":"C Natale","year":"2021","unstructured":"Natale C, McLellan DM, Yousif A, et al. Review of intralesional collagenase clostridium histolyticum injection therapy and related combination therapies in the treatment of Peyronie\u2019s disease (an update). Sex Med Rev. 2021;9(2):340\u20139.","journal-title":"Sex Med Rev."},{"key":"3614_CR11","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/978-3-319-17202-6_14","volume-title":"Peyronie\u2019s disease. A comprehensive guide","author":"G Paulis","year":"2015","unstructured":"Paulis G. Combination therapy (in the treatment of Peyronie\u2019s disease). In: Cavallini G, Paulis G, editors. Peyronie\u2019s disease. A comprehensive guide. Switzerland: Springer International Publishing; 2015. p. 97\u2013105."},{"issue":"4","key":"3614_CR12","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1038\/sj.pcan.4500568","volume":"5","author":"LM Eri","year":"2002","unstructured":"Eri LM, Thomassen H, Brennhovd B, et al. Accuracy and repeatability of prostate volume measurements by transrectal ultrasound. Prostate Cancer Prostatic Dis. 2002;5(4):273\u20138.","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"4","key":"3614_CR13","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1159\/000100836","volume":"78","author":"JS Lee","year":"2007","unstructured":"Lee JS, Chung BH. Transrectal ultrasound versus magnetic resonance imaging in the estimation of prostate volume as compared with radical prostatectomy specimens. Urol Int. 2007;78(4):323\u20137.","journal-title":"Urol Int"},{"key":"3614_CR14","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.acuro.2018.08.005","volume":"43","author":"L Gallo","year":"2019","unstructured":"Gallo L, Sarnacchiaro P. Ten-year experience with multimodal treatment for acute phase Peyronie\u2019s disease: a real life clinical report. Actas Urol Esp (Engl Ed). 2019;43:182\u20139.","journal-title":"Actas Urol Esp (Engl Ed)."},{"key":"3614_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2147\/RRU.S97194","volume":"8","author":"G Paulis","year":"2016","unstructured":"Paulis G, Barletta D, Turchi P, et al. Efficacy and safety evaluation of pentoxifylline associated with other antioxidants in medical treatment of Peyronie\u2019s disease: a case\u2013control study. Res Rep Urol. 2016;8:1. https:\/\/doi.org\/10.2147\/RRU.S97194.","journal-title":"Res Rep Urol."},{"issue":"6","key":"3614_CR16","doi-asserted-by":"publisher","first-page":"403","DOI":"10.2174\/1871528112666131205112432","volume":"12","author":"G Paulis","year":"2013","unstructured":"Paulis G, Cavallini G, De Giorgio G, et al. Long-term multimodal therapy (verapamil associated with propolis, blueberry, vitamin E and local diclofenac) on patients with Peyronie\u2019s disease (chronic inflammation of the tunica albuginea). Results of a controlled study. Inflamm Allergy Drug Targets. 2013;12(6):403\u20139.","journal-title":"Inflamm Allergy Drug Targets"},{"issue":"2","key":"3614_CR17","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1038\/ncpuro0409","volume":"3","author":"WO Brant","year":"2006","unstructured":"Brant WO, Dean RC, Lue TF. Treatment of Peyronie\u2019s disease with oral pentoxifylline. Nat Clin Pract Urol. 2006;3(2):111\u20135.","journal-title":"Nat Clin Pract Urol"},{"issue":"2","key":"3614_CR18","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1038\/aja.2010.117","volume":"13","author":"JF Smith","year":"2011","unstructured":"Smith JF, Shindel AW, Huang YC, et al. Pentoxifylline treatment and penile calcifications in men with Peyronie\u2019s disease. Asian J Androl. 2011;13(2):322\u20135.","journal-title":"Asian J Androl"},{"issue":"5","key":"3614_CR19","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1038\/nrurol.2010.53","volume":"7","author":"S Payton","year":"2010","unstructured":"Payton S. Therapeutic benefit of pentoxifylline for Peyronie\u2019s disease. Nat Rev Urol. 2010;7(5):237.","journal-title":"Nat Rev Urol"},{"issue":"7","key":"3614_CR20","doi-asserted-by":"publisher","first-page":"23","DOI":"10.5539\/gjhs.v6n7p23","volume":"6","author":"M Alizadeh","year":"2014","unstructured":"Alizadeh M, Karimi F, Fallah MR. Evaluation of verapamil efficacy in Peyronie\u2019s disease comparing with pentoxifylline. Global J Health Sci. 2014;6(7):23\u201330.","journal-title":"Global J Health Sci"},{"issue":"1","key":"3614_CR21","doi-asserted-by":"publisher","first-page":"36","DOI":"10.4081\/aiua.2013.1.36","volume":"85","author":"F Ciociola","year":"2013","unstructured":"Ciociola F, Colpi GM. Peyronie\u2019s disease: a \u201ctriple oxygenant therapy.\u201d Arch Ital Urol Androl. 2013;85(1):36\u201340.","journal-title":"Arch Ital Urol Androl"},{"issue":"8","key":"3614_CR22","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1111\/and.12178","volume":"46","author":"V Favilla","year":"2014","unstructured":"Favilla V, Russo GI, Privitera S, et al. Combination of intralesional verapamil and oral antioxidants for Peyronie\u2019s disease: a prospective, randomised controlled study. Andrologia. 2014;46(8):936\u201342.","journal-title":"Andrologia"},{"key":"3614_CR23","doi-asserted-by":"publisher","first-page":"e936146","DOI":"10.12659\/AJCR.936146","volume":"23","author":"G Paulis","year":"2022","unstructured":"Paulis G, De Giorgio G. Complete plaque regression in patients with Peyronie\u2019s disease. After multimodal treatment with antioxidants a report of 2 cases. Am J Case Rep. 2022;23:e936146. https:\/\/doi.org\/10.12659\/AJCR.936146.","journal-title":"Am J Case Rep."},{"issue":"6","key":"3614_CR24","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1111\/bju.12812","volume":"114","author":"KD Kwon","year":"2014","unstructured":"Kwon KD, Choi MJ, Park JM, et al. Silencing histone deacetylase 2 using small hairpin RNA induces regression of fibrotic plaque in a rat model of Peyronie\u2019s disease. BJU Int. 2014;114(6):926\u201336.","journal-title":"BJU Int"},{"issue":"1","key":"3614_CR25","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1111\/j.1743-6109.2011.02502.x","volume":"9","author":"R Tal","year":"2012","unstructured":"Tal R, Hall MS, Alex B, Choi J, Mulhall JP. Peyronie\u2019s disease in teenagers. J Sex Med. 2012;9(1):302\u20138.","journal-title":"J Sex Med"},{"issue":"1","key":"3614_CR26","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.jep.2013.06.004","volume":"149","author":"MC B\u00fafalo","year":"2013","unstructured":"B\u00fafalo MC, Ferreira I, Costa G, et al. Propolis and its constituent caffeic acid suppress LPS-stimulated pro-inflammatory response by blocking NF-\u03baB and MAPK activation in macrophages. J Ethnopharmacol. 2013;149(1):84\u201392.","journal-title":"J Ethnopharmacol"},{"key":"3614_CR27","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1111\/j.1582-4934.2004.tb00276.x","volume":"8","author":"M Ebadi","year":"2004","unstructured":"Ebadi M, Sharma SK, Wanpen S, Amornpan A. Coenzyme Q10 inhibits mitochondrial complex-1 down-regulation and nuclear factor-kappa B activation. J Cell Mol Med. 2004;8:213\u201322.","journal-title":"J Cell Mol Med"},{"issue":"6","key":"3614_CR28","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1007\/s00394-010-0092-0","volume":"49","author":"A Karlsen","year":"2010","unstructured":"Karlsen A, Paur I, B\u00f8hn SK, et al. Bilberry juice modulates plasma concentration of NF-kappaB related inflammatory markers in subjects at increased risk of CVD. Eur J Nutr. 2010;49(6):345\u201355.","journal-title":"Eur J Nutr"},{"key":"3614_CR29","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1016\/j.fsi.2019.08.041","volume":"93","author":"DM Zhang","year":"2019","unstructured":"Zhang DM, Guo ZX, Zhao YL, et al. l-Carnitine regulated Nrf2\/Keap1 activation in vitro and in vivo and protected oxidized fish oil-induced inflammation response by inhibiting the NF-\u03baB signaling pathway in Rhynchocypris lagowski Dybowski. Fish Shellfish Immunol. 2019;93:1100\u201310.","journal-title":"Fish Shellfish Immunol"},{"issue":"8","key":"3614_CR30","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1016\/j.lfs.2005.05.103","volume":"78","author":"I G\u00fcl\u00e7in","year":"2006","unstructured":"G\u00fcl\u00e7in I. Antioxidant and antiradical activities of l-carnitine. Life Sci. 2006;78(8):803\u201311.","journal-title":"Life Sci"},{"key":"3614_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2020.107347","volume":"92","author":"HA Mohamed","year":"2021","unstructured":"Mohamed HA, Said RS. Coenzyme Q10 attenuates inflammation and fibrosis implicated in radiation enteropathy through suppression of NF-kB\/TGF-\u03b2\/MMP-9 pathways. Int Immunopharmacol. 2021;92: 107347. https:\/\/doi.org\/10.1016\/j.intimp.2020.107347.","journal-title":"Int Immunopharmacol"},{"issue":"1","key":"3614_CR32","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1186\/s12917-019-1868-y","volume":"15","author":"MY Tian","year":"2019","unstructured":"Tian MY, Fan JH, Zhuang ZW, et al. Effects of silymarin on p65 NF-\u03baB, p38 MAPK and CYP450 in LPS-induced hoof dermal inflammatory cells of dairy cows. BMC Vet Res. 2019;15(1):127.","journal-title":"BMC Vet Res"},{"key":"3614_CR33","first-page":"6303","volume":"9","author":"Y Wang","year":"2015","unstructured":"Wang Y, Wang R, Wang Y, et al. Ginkgo biloba extract mitigates liver fibrosis and apoptosis by regulating p38 MAPK, NF-\u03baB\/I\u03baB\u03b1, and Bcl-2\/Bax signaling. Drug Des Dev Ther. 2015;9:6303\u201317.","journal-title":"Drug Des Dev Ther"},{"issue":"4","key":"3614_CR34","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1007\/s10072-014-1965-4","volume":"36","author":"WG Wang","year":"2015","unstructured":"Wang WG, Xiu RJ, Xu ZW, et al. Protective effects of Vitamin C against spinal cord injury-induced renal damage through suppression of NF-\u03baB and proinflammatory cytokines. Neurol Sci. 2015;36(4):521\u20136.","journal-title":"Neurol Sci"},{"issue":"1\u20132","key":"3614_CR35","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.jneuroim.2005.08.003","volume":"169","author":"JP Godbout","year":"2005","unstructured":"Godbout JP, Berg BM, Krzyszton C, Johnson RW. Alpha-tocopherol attenuates NFkappaB activation and pro-inflammatory cytokine production in brain and improves recovery from lipopolysaccharide-induced sickness behavior. J Neuroimmunol. 2005;169(1\u20132):97\u2013105.","journal-title":"J Neuroimmunol"},{"issue":"1","key":"3614_CR36","doi-asserted-by":"publisher","first-page":"82","DOI":"10.3109\/08923970903183557","volume":"32","author":"TW Costantini","year":"2010","unstructured":"Costantini TW, Deree J, Peterson CY, et al. Pentoxifylline modulates p47phox activation and downregulates neutrophil oxidative burst through PKA-dependent and -independent mechanisms. Immunopharmacol Immunotoxicol. 2010;32(1):82\u201391.","journal-title":"Immunopharmacol Immunotoxicol"},{"issue":"1","key":"3614_CR37","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.yexmp.2014.05.009","volume":"97","author":"VR Sunil","year":"2014","unstructured":"Sunil VR, Vayas KN, Cervelli JA, et al. Pentoxifylline attenuates nitrogen mustard-induced acute lung injury, oxidative stress and inflammation. Exp Mol Pathol. 2014;97(1):89\u201398.","journal-title":"Exp Mol Pathol"},{"issue":"1\u20133","key":"3614_CR38","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1007\/BF02790131","volume":"47","author":"JP Freitas","year":"1995","unstructured":"Freitas JP, Filipe PM. Pentoxifylline. A hydroxyl radical scavenger. Biol Trace Elem Res. 1995;47(1\u20133):307\u201311.","journal-title":"Biol Trace Elem Res"},{"issue":"4","key":"3614_CR39","first-page":"427","volume":"34","author":"Q Ji","year":"2004","unstructured":"Ji Q, Zhang L, Jia H, Xu J. Pentoxifylline inhibits endotoxin-induced NF-kappa B activation and associated production of proinflammatory cytokines. Ann Clin Lab Sci. 2004;34(4):427\u201336.","journal-title":"Ann Clin Lab Sci"},{"issue":"5","key":"3614_CR40","doi-asserted-by":"publisher","first-page":"431","DOI":"10.4062\/biomolther.2020.090","volume":"28","author":"F Jin","year":"2020","unstructured":"Jin F, Li X, Lee HJ, Lee CJ. diclofenac inhibits phorbol ester-induced gene expression and production of MUC5AC mucin via affecting degradation of IkB\u03b1 and translocation of NF-kB p65 in NCI-H292 cells. Biomol Ther (Seoul). 2020;28(5):431\u20136.","journal-title":"Biomol Ther (Seoul)."},{"issue":"5","key":"3614_CR41","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1111\/j.1365-2125.1991.tb05576.x","volume":"31","author":"J Radermacher","year":"1991","unstructured":"Radermacher J, Jentsch D, Scholl MA, et al. Diclofenac concentrations in synovial fluid and plasma after cutaneous application in inflammatory and degenerative joint disease. Br J Clin Pharmacol. 1991;31(5):537\u201341.","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"3614_CR42","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/j.eururo.2012.05.040","volume":"62","author":"K Hatzimouratidis","year":"2012","unstructured":"Hatzimouratidis K, Eardley I, Giuliano F, et al. EAU guidelines on penile curvature. Eur Urol. 2012;62(3):543\u201352.","journal-title":"Eur Urol"},{"issue":"2","key":"3614_CR43","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1007\/s00345-019-02928-y","volume":"38","author":"JF McCauley","year":"2020","unstructured":"McCauley JF, Dean RC. Diagnostic utility of penile ultrasound in Peyronie\u2019s disease. World J Urol. 2020;38(2):263\u20138.","journal-title":"World J Urol"},{"issue":"3","key":"3614_CR44","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1097\/MOU.0000000000000754","volume":"30","author":"M Parmar","year":"2020","unstructured":"Parmar M, Masterson JM, Masterson TA 3rd. The role of imaging in the diagnosis and management of Peyronie\u2019s disease. Curr Opin Urol. 2020;30(3):283\u20139.","journal-title":"Curr Opin Urol"}],"container-title":["Journal of Medical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-022-03614-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13256-022-03614-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-022-03614-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,22]],"date-time":"2023-02-22T13:54:09Z","timestamp":1677074049000},"score":1,"resource":{"primary":{"URL":"https:\/\/jmedicalcasereports.biomedcentral.com\/articles\/10.1186\/s13256-022-03614-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,8]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["3614"],"URL":"https:\/\/doi.org\/10.1186\/s13256-022-03614-1","relation":{},"ISSN":["1752-1947"],"issn-type":[{"value":"1752-1947","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,8]]},"assertion":[{"value":"20 May 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 October 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patients for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The authors have no conflicts of interest to declare.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"359"}}